Seeking Alpha

Pfizer (PFE +1%) says that clinical trials for Chantix/Champix, a smoking cessation drug for...

Pfizer (PFE +1%) says that clinical trials for Chantix/Champix, a smoking cessation drug for patients with major depressive disorder, met its primary and secondary endpoints . Subjects had a higher likelihood of quitting at week 12 (primary endpoint) and at week 52 (key secondary endpoint). In addition, psychiatric scales included for safety assessments did not show a difference between the drug and placebo.
From other sites
Comments (3)
  • spute
    , contributor
    Comments (75) | Send Message
     
    ...I don't believe ANYthing Pfizer says.
    16 Oct 2012, 01:48 PM Reply Like
  • chopchop0
    , contributor
    Comments (4006) | Send Message
     
    I do. they keep printing new 52-week highs.
    16 Oct 2012, 01:55 PM Reply Like
  • spald_fr
    , contributor
    Comments (2807) | Send Message
     
    These are not my father's smokers. Somehow a whole generation of smokers reduced from 70% of the population to 25% without pyschotropic medicines.
    16 Oct 2012, 03:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs